2. Search Result
Search Result
Results for "

Imiquimod

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

3

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0180
    Imiquimod
    Maximum Cited Publications
    35 Publications Verification

    R 837

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod
  • HY-B0180B
    Imiquimod maleate
    Maximum Cited Publications
    35 Publications Verification

    R 837 maleate

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod maleate
  • HY-B0180A
    Imiquimod hydrochloride
    Maximum Cited Publications
    35 Publications Verification

    R 837 hydrochloride

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod hydrochloride
  • HY-139374
    Zabedosertib
    1 Publications Verification

    BAY 1834845

    		 IRAK Inflammation/Immunology
    Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with immunomodulatory potential, IC50 is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .
    Zabedosertib
  • HY-B0180R
    Imiquimod (Standard)

    		Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod (Standard)
  • HY-143974S
    Imiquimod impurity 1-d6

    		Drug Metabolite Isotope-Labeled Compounds Others
    Imiquimod impurity 1-d6 is the deuterium labeled Imiquimod impurity 1[1].
    Imiquimod impurity 1-d6
  • HY-B0180S
    Imiquimod-d6

    R 837-d6

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
    Imiquimod-d6
  • HY-B0180S1
    Imiquimod-d9

    R 837-d9

    		 Isotope-Labeled Compounds Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
    Imiquimod-d9
  • HY-143976S
    3-Hydroxy imiquimod-d4

    		Isotope-Labeled Compounds Others
    3-Hydroxy imiquimod-d4 is the deuterium labeled 3-Hydroxy imiquimod.
    3-Hydroxy imiquimod-d4
  • HY-155548
    RORγt inverse agonist 31

    		ROR Inflammation/Immunology
    RORγt inverse agonist 31 (14g) is a potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 0.428 μM. RORγt inverse agonist 31 can alleviate the severity of Imiquimod (HY-B0180)-induced psoriasis in mice .
    RORγt inverse agonist 31
  • HY-136527
    BMS-986251

    		ROR Interleukin Related Inflammation/Immunology
    BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis) .
    BMS-986251
  • HY-157456
    RIPK1-IN-19

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-19 (compound 10b) is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
    RIPK1-IN-19
  • HY-160097
    AXC-666

    		ADC Cytotoxin Inflammation/Immunology Cancer
    AXC-666, an immune agonist, is a Imiquimod (HY-B0180) derivative. AXC-666 can be used for the synthesis of antibody-drug conjugate (ADC) .
    AXC-666
  • HY-120225
    NJK14047

    		p38 MAPK Inflammation/Immunology
    NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice .
    NJK14047
  • HY-163176
    WB518

    		STAT Inflammation/Immunology
    WB518 is a potent STAT3 inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17 .
    WB518
  • HY-150745
    ODN 24987

    		Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24987 is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .
    ODN 24987
  • HY-150745A
    ODN 24987 sodium

    		Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24987 sodium is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 sodium can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .
    ODN 24987 sodium
  • HY-169007
    STAT3-IN-34

    		STAT Inflammation/Immunology
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice .
    STAT3-IN-34
  • HY-155505
    AHR agonist 4

    		Aryl Hydrocarbon Receptor Inflammation/Immunology
    AHR agonist 4 (compound 24e) is an agonist of Aryl hydrocarbon receptor (AHR), assocaited with the immune balance of Th17/22 and Treg cells. AHR agonist 4 serves as a lead compound for anti-psoriasis drug, alleviates imiquimod (IMQ)-induced psoriasis-like skin lesion . AHR agonist 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AHR agonist 4
  • HY-131040
    NLRP3-IN-NBC6

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca 2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .
    NLRP3-IN-NBC6
  • HY-155244
    12R-LOX-IN-2

    		Lipoxygenase DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .
    12R-LOX-IN-2
  • HY-116330A
    Hyperforin dicyclohexylammonium salt
    1 Publications Verification

    Hyperforin DCHA

    		 TRP Channel Calcium Channel Neurological Disease
    Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin dicyclohexylammonium salt
  • HY-155243
    12R-LOX-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .
    12R-LOX-IN-1
  • HY-116330
    Hyperforin

    		Calcium Channel TRP Channel Neurological Disease Inflammation/Immunology
    Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin
  • HY-116330AR
    Hyperforin dicyclohexylammonium salt (Standard)

    		TRP Channel Calcium Channel Neurological Disease
    Hyperforin (dicyclohexylammonium salt) (Standard) is the analytical standard of Hyperforin (dicyclohexylammonium salt). This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin dicyclohexylammonium salt (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: